| Methods |
4‐ to 6‐week placebo run‐in; inclusion criteria= supine DBP 95‐115 mm Hg on 2 consecutive visits after beginning of placebo run‐in; 8‐week double‐blind treatment |
| Participants |
Captopril 25 mg twice daily: n=77(60 males,17 females); mean age=52 years; baseline supine SBP=156 mm Hg, DBP=101 mm Hg;
Captopril 50 mg twice daily: n=71(50 males,21 females); mean age=52 years; baseline supine SBP=154 mm Hg, DBP=101 mm Hg;
Captopril 100 mg twice daily: n=69(44 males,25 females); mean age=55 years; baseline supine SBP=158 mm Hg, DBP=102 mm Hg;
Placebo: n=77(53 males,24 females); mean age=53 years; baseline supine SBP=157 mm Hg, DBP=102 mm Hg |
| Interventions |
Captopril 25 mg twice daily;
Captopril 50 mg twice daily;
Captopril 100 mg twice daily;
Placebo |
| Outcomes |
Percent change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported; baseline SD not reported; imputed overall trial mean SD of change for SBP and DBP; percent change in SBP data from text, p. III‐110; percent change in DBP data from Figure 1, p. III‐110; percent change in BP has been converted to absolute BP change data; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
